Donald Trump hints at retaliation if India doesn't export key Covid-19 drug

Trump said that during his recent phone call with Modi, the latter had said he will consider the request of releasing the order to the US

Trump Modi
US President Donald Trump and Prime Minister Narendra Modi wave to the crowd at Sardar Patel Stadium in Ahmedabad. AP
ANI United States
2 min read Last Updated : Apr 07 2020 | 8:08 AM IST
US President Donald Trump on Monday hinted at a possible retaliation if India does not lift its hold on the export of Hydroxychloroquine, the anti-malaria drug used in the treatment of coronavirus patients.

Trump speaking from the White House during the Coronavirus taskforce briefing said that India does very well with the US and he sees no reason why India would not lift the hold on the US order of the medicine.

He said, "'didn't hear that that was his (Modi) decision. I know that he stopped it for other countries I spoke to him yesterday, very very good talk, and we'll see whether or not that stays I wouldn't be surprised if he would you know because India's does very well with the United States,"

Trump said that during his recent phone call with Modi, the latter had said he will consider the request of releasing the order to the US.


The US President added, "So I wouldn't be surprised if that was a decision he'd have to tell me that I spoke to him Sunday morning I called him and I said we'd appreciate your allowing our supply to come out. If he doesn't allow it to come out,"

Trump said that India and the US have had good trade agreements and hinted at possible retaliation if India decided not to lift the hold. US President Donald Trump on Saturday had said that he has requested Prime Minister Narendra Modi to supply Hydroxychloroquine tablets that can be used to treat COVID-19 patients.


"After call today with Indian Prime Minister Narendra Modi, India is giving serious consideration to releasing the hold it put on a US order for hydroxychloroquine," Trump announced at the White House Coronavirus task force briefing.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusUS President Donald TrumpUS India relations PM Narendra Modi

Next Story